Transcenta Receives IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited announces that TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, has received IND clearance from the Center for Drug Evaluation (CDE) of China'sNational Medical Products Administration (NMPA). Transcenta presented the latest progress of TST003 program at the 10th TEMTIA meeting in October 2022. Preclinical data showed that TST003 blocks EMT and displays potent single agent anti-tumor activities in PDX models of multiple difficult-to-treat solid tumors.

TST003 also received its IND clearance from U.S. Food and Drug Administration (FDA) in September, 2022.